JNJ
$112.26
Johnson & Johnson
$1.27
1.14%
Earnings Details
3rd Quarter September 2016
Tuesday, October 18, 2016 6:40:00 AM
Tweet Share Watch
Summary

Johnson & Johnson Beats

Johnson & Johnson (JNJ) reported 3rd Quarter September 2016 earnings of $1.68 per share on revenue of $17.8 billion. The consensus earnings estimate was $1.65 per share on revenue of $17.7 billion. The Earnings Whisper number was $1.66 per share. Revenue grew 4.2% on a year-over-year basis.

The company said it now expects 2016 earnings of $6.68 to $6.73 per share on revenue of $71.5 billion to $72.2 billion. The company's previous guidance was earnings of $6.63 to $6.73 per share and the current consensus earnings estimate is $6.69 per share on revenue of $72.00 billion for the year ending December 31, 2016.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.

Results
Reported Earnings
$1.68
Earnings Whisper
$1.66
Consensus Estimate
$1.65
Reported Revenue
$17.82 Bil
Revenue Estimate
$17.69 Bil
Growth
Earnings Growth
Revenue Growth
Power Rating
Grade
Earnings Release

Johnson & Johnson Reports 2016 Third-Quarter Results:

Johnson & Johnson (JNJ) today announced sales of $17.8 billion for the third quarter of 2016, an increase of 4.2% as compared to the third quarter of 2015. Operational sales results increased 4.3% and the negative impact of currency was 0.1%. Domestic sales increased 6.7%. International sales increased 1.5%, reflecting operational growth of 1.7% and a negative currency impact of 0.2%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 5.9%, domestic sales increased 7.3% and international sales increased 4.2%.* Operations in Venezuela negatively impacted worldwide operational sales growth by 30 basis points, and international sales growth by 70 basis points.

Net earnings and diluted earnings per share for the third quarter of 2016 were $4.3 billion and $1.53, respectively. Third quarter 2016 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.2 billion. Third quarter 2015 net earnings included after-tax intangible amortization expense of approximately $0.4 billion and a charge for after-tax special items of approximately $0.4 billion. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.7 billion and adjusted diluted earnings per share were $1.68, representing increases of 12.2% and 12.8%, respectively, as compared to the same period in 2015.* On an operational basis, adjusted diluted earnings per share also increased 12.8%.* A reconciliation of non-GAAP financial measures is included as an accompanying schedule.

"Our third-quarter results reflect the success of our new product launches and the strength of our core businesses, driven by strong growth in our Pharmaceuticals business. With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion," said Alex Gorsky, Chairman and Chief Executive Officer. "Our broad-based business model, strategic investments and talented colleagues position us well for continued leadership in health care."

The Company maintained its sales guidance for the full-year 2016 of $71.5 billion to $72.2 billion. Additionally, the Company increased its adjusted earnings guidance for full-year 2016 to $6.68 - $6.73 per share.*

Worldwide Consumer sales of $3.3 billion for the third quarter 2016 represented a decrease of 1.6% versus the prior year, consisting of an operational increase of 0.1% and a negative impact from currency of 1.7%. Domestic sales increased 1.1%; international sales decreased 3.3%, which reflected an operational decrease of 0.6% and a negative currency impact of 2.7%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales decreased 0.4%, domestic sales decreased 1.5% and international sales increased 0.3%*. Operations in Venezuela negatively impacted worldwide Consumer operational sales growth by 110 basis points and international sales growth by 180 basis points.

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were negatively impacted by lower trade inventory levels, primarily in the U.S. Positive contributors to Consumer operational sales results included LISTERINE? oral care products; AVEENO? skin care products and digestive health products and international smoking aids in over-the-counter products.

Worldwide Pharmaceutical sales of $8.4 billion for the third quarter 2016 represented an increase of 9.2% versus the prior year with an operational increase of 9.0% and a positive impact from currency of 0.2%. Domestic sales increased 11.8%; international sales increased 5.4%, which reflected an operational increase of 5.0% and a positive currency impact of 0.4%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 10.7%, domestic sales increased 13.0% and international sales increased 7.0%.*

Worldwide operational results, excluding the net impact of acquisitions, divestitures and hepatitis C sales, were driven by new products and the strength of core products. Strong growth in new products include IMBRUVICA? (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer; DARZALEX? (daratumumab), for the treatment of patients with multiple myeloma; and XARELTO? (rivaroxaban), an oral anticoagulant.

Additional contributors to operational sales growth included STELARA? (ustekinumab), REMICADE? (infliximab) and SIMPONI?/SIMPONI ARIA? (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; and INVEGA? SUSTENNA?/XEPLION?/TRINZA? (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults.

During the quarter, the U.S. Food and Drug Administration (FDA) approved INVOKAMET? XR (canagliflozin/metformin HCl extended-release) for first-line treatment of adults with type 2 diabetes, and STELARA? (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease. The Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of STELARA? for the treatment of adults with moderately to severely active Crohn’s disease.

Additionally, regulatory applications for approval were submitted to the FDA and European Medicines Agency (EMA) for DARZALEX? in combination with standard-of-care regimens for patients with multiple myeloma who have received at least one prior therapy. DARZALEX? also received Breakthrough Therapy Designation from the FDA for this pending indication. The FDA also granted Breakthrough Therapy Designation to esketamine for major depressive disorder with imminent risk for suicide. Regulatory applications for approval were also submitted to the FDA for sirukumab in rheumatoid arthritis, and to EMA for a darunavir-based single tablet regimen for the treatment of HIV-1.

Worldwide Medical Devices sales of $6.2 billion for the third quarter 2016 represented an increase of 1.1% versus the prior year consisting of an operational increase of 0.7% and a positive currency impact of 0.4%. Domestic sales increased 1.4%; international sales increased 0.7%, which reflected an operational decline of 0.2% and a positive currency impact of 0.9%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 3.1%, domestic sales increased 2.3% and international sales increased 3.9%.*

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by electrophysiology products in the Cardiovascular business; endocutters and energy in the Advanced Surgery business; ACUVUE? contact lenses in the Vision Care business; and joint reconstruction and trauma products in the Orthopaedics business.

During the quarter, a definitive agreement was announced to acquire Abbott Medical Optics, a wholly-owned subsidiary of Abbott Laboratories, for $4.325 billion in cash. Acclarent announced the U.S. launch of ACCLARENT AERA(TM), the first balloon dilation intervention approved by the FDA for Eustachian Tube Dysfunction.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,900 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Operational sales growth excluding the net impact of acquisitions, divestitures and hepatitis C sales, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company’s website at www.investor.jnj.com. Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can be found on the company’s website at www.investor.jnj.com.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; market conditions and the possibility that the on-going share repurchase program may be delayed, suspended or discontinued; the impact of business combinations and divestitures; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; increased scrutiny of the health care industry by government agencies; and the potential failure to meet obligations in compliance agreements with government bodies. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
THIRD QUARTER
NINE MONTHS
Percent Change
Percent Change
2016
2015
Total
Operations
Currency
2016
2015
Total
Operations
Currency
Sales to customers by
segment of business
Consumer
U.S.
$
1,291
1,277
1.1
%
1.1
-
$
4,033
3,991
1.1
%
1.1
-
International
1,970
2,037
(3.3)
(0.6)
(2.7)
5,842
6,196
(5.7)
0.1
(5.8)
3,261
3,314
(1.6)
0.1
(1.7)
9,875
10,187
(3.1)
0.4
(3.5)
Pharmaceutical
U.S.
5,042
4,509
11.8
11.8
-
15,123
13,423
12.7
12.7
-
International
3,358
3,185
5.4
5.0
0.4
10,109
9,943
1.7
4.2
(2.5)
8,400
7,694
9.2
9.0
0.2
25,232
23,366
8.0
9.1
(1.1)
Medical Devices
U.S.
3,048
3,005
1.4
1.4
-
9,118
8,980
1.5
1.5
-
International
3,111
3,089
0.7
(0.2)
0.9
9,559
9,730
(1.8)
0.5
(2.3)
6,159
6,094
1.1
0.7
0.4
18,677
18,710
(0.2)
1.0
(1.2)
U.S.
9,381
8,791
6.7
6.7
-
28,274
26,394
7.1
7.1
-
International
8,439
8,311
1.5
1.7
(0.2)
25,510
25,869
(1.4)
1.8
(3.2)
Worldwide
$ 17,820
17,102
4.2
%
4.3
(0.1)
$ 53,784
52,263
2.9
%
4.5
(1.6)
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
THIRD QUARTER
NINE MONTHS
Percent Change
Percent Change
2016
2015
Total
Operations
Currency
2016
2015
Total
Operations
Currency
Sales to customers by
geographic area
U.S.
$
9,381
8,791
6.7
%
6.7
-
$ 28,274
26,394
7.1
%
7.1
-
Europe
3,832
3,802
0.8
3.2
(2.4)
11,769
11,993
(1.9)
0.5
(2.4)
Western Hemisphere excluding U.S.
1,396
1,463
(4.6)
(1.3)
(3.3)
4,269
4,603
(7.3)
4.4
(11.7)
Asia-Pacific, Africa
3,211
3,046
5.4
1.4
4.0
9,472
9,273
2.1
2.1
0.0
International
8,439
8,311
1.5
1.7
(0.2)
25,510
25,869
(1.4)
1.8
(3.2)
Worldwide
$ 17,820
17,102
4.2
%
4.3
(0.1)
$ 53,784
52,263
2.9
%
4.5
(1.6)
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
THIRD QUARTER
2016
2015
Percent
Percent
Percent
Increase
Amount
to Sales
Amount
to Sales
(Decrease)
Sales to customers
$
17,820
100.0
$
17,102
100.0
4.2
Cost of products sold
5,486
30.8
5,224
30.5
5.0
Selling, marketing and administrative expenses
4,772
26.8
5,081
29.7
(6.1)
Research and development expense
2,178
12.2
2,154
12.6
1.1
In-process research and development
-
-
10
0.1
Interest (income) expense, net
95
0.5
91
0.5
Other (income) expense, net
(54)
(0.2)
420
2.5
Restructuring
62
0.3
-
-
Earnings before provision for taxes on income
5,281
29.6
4,122
24.1
28.1
Provision for taxes on income
1,009
5.6
764
4.5
32.1
Net earnings
$
4,272
24.0
$
3,358
19.6
27.2
Net earnings per share (Diluted)
$
1.53
$
1.20
27.5
Average shares outstanding (Diluted)
2,785.4
2,807.2
Effective tax rate
19.1
%
18.5
%
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income
$
5,831
32.7
$
5,212
30.5
11.9
Net earnings
$
4,683
26.3
$
4,172
24.4
12.2
Net earnings per share (Diluted)
$
1.68
$
1.49
12.8
Effective tax rate
19.7
%
20.0
%
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
NINE MONTHS
2016
2015
Percent
Percent
Percent
Increase
Amount
to Sales
Amount
to Sales
(Decrease)
Sales to customers
$
53,784
100.0
$
52,263
100.0
2.9
Cost of products sold
16,151
30.0
15,863
30.4
1.8
Selling, marketing and administrative expenses
14,636
27.2
15,312
29.3
(4.4)
Research and development expense
6,455
12.0
6,182
11.8
4.4
In-process research and development
29
0.1
10
0.0
Interest (income) expense, net
274
0.5
317
0.6
Other (income) expense, net
464
0.9
(859)
(1.6)
Restructuring
296
0.5
-
-
Earnings before provision for taxes on income
15,479
28.8
15,438
29.5
0.3
Provision for taxes on income
2,753
5.1
3,244
6.2
(15.1)
Net earnings
$
12,726
23.7
$
12,194
23.3
4.4
Net earnings per share (Diluted)
$
4.55
$
4.33
5.1
Average shares outstanding (Diluted)
2,796.6
2,817.1
Effective tax rate
17.8
%
21.0
%
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income
$
17,656
32.8
$
17,090
32.7
3.3
Net earnings
$
14,403
26.8
$
13,402
25.6
7.5
Net earnings per share (Diluted)
$
5.15
$
4.76
8.2
Effective tax rate
18.4
%
21.6
%
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Third Quarter
% Incr. /
Nine Months YTD
% Incr. /
(Dollars in Millions Except Per Share Data)
2016
2015
(Decr.)
2016
2015
(Decr.)
Earnings before provision for taxes on income - as reported
$ 5,281
4,122
28.1
%
$ 15,479
15,438
0.3
%
Intangible asset amortization expense
319
639
927
1,269
Restructuring/Other (1)
109
-
387
-
Litigation expense, net
55
409
721
141
DePuy ASR(TM) Hip program
-
-
-
148
In-process research and development
-
10
29
10
Other
67
32
113
84
Earnings before provision for taxes on income - as adjusted
$ 5,831
5,212
11.9
%
$ 17,656
17,090
3.3
%
Net Earnings - as reported
$ 4,272
3,358
27.2
%
$ 12,726
12,194
4.4
%
Intangible asset amortization expense
236
437
679
893
Restructuring/Other
76
-
293
-
Litigation expense, net
46
348
595
118
DePuy ASR(TM) Hip program
-
-
-
130
In-process research and development
-
6
23
6
Other
53
23
87
61
Net Earnings - as adjusted
$ 4,683
4,172
12.2
%
$ 14,403
13,402
7.5
%
Diluted Net Earnings per share - as reported
$
1.53
1.20
27.5
%
$
4.55
4.33
5.1
%
Intangible asset amortization expense
0.08
0.16
0.24
0.32
Restructuring/Other
0.03
-
0.11
-
Litigation expense, net
0.02
0.12
0.21
0.04
DePuy ASR(TM) Hip program
-
-
-
0.05
In-process research and development
-
-
0.01
-
Other
0.02
0.01
0.03
0.02
Diluted Net Earnings per share - as adjusted
$
1.68
1.49
12.8
%
$
5.15
4.76
8.2
%
Operational Diluted Net Earnings per share - as adjusted at 2014 foreign currency exchange rates
1.63
5.22
Impact of currency at 2015 foreign currency exchange rates
$
-
(0.14)
$
0.04
(0.46)
Operational Diluted Net Earnings per share - as adjusted at 2015 foreign currency exchange rates $
1.68
1.49
12.8
%
$
5.19
4.76
9.0
%
(1) Includes $3M recorded in cost of products sold and $44M recorded in other (income) expense for the third quarter.
Includes $27M recorded in cost of products sold and $64M recorded in other (income) expense for nine months YTD.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions, Divestitures, and Hepatitis C Sales(1)
THIRD QUARTER 2016 ACTUAL vs. 2015 ACTUAL
Segments
Consumer
Pharmaceutical
Medical Devices
Total
Operational %(2)
WW As Reported:
0.1%
9.0%
0.7%
4.3%
U.S.
1.1%
11.8%
1.4%
6.7%
International
(0.6)%
5.0%
(0.2)%
1.7%
Wound Care/Other
SPLENDA?
2.1
0.4
U.S.
4.0
0.6
International
1.0
0.2
Cardiovascular
Cordis
2.3
0.9
U.S.
1.1
0.4
International
3.7
1.4
Skin Care
(2.3)
Vogue
(5.8)
(0.4)
U.S.
0.0
(0.8)
International
0.0
Other Neuroscience
Controlled Substance Raw Material and API Business
0.7
0.3
U.S.
0.9
0.4
International
0.4
0.1
All Other Acquisitions and Divestitures
(0.3)
0.0
0.1
0.0
U.S.
(0.8)
0.0
(0.2)
(0.2)
International
(0.1)
0.0
0.4
0.2
WW Ops excluding Acquisitions and Divestitures
(0.4)%
9.7%
3.1%
5.5%
U.S.
(1.5)%
12.7%
2.3%
7.1%
International
0.3%
5.4%
3.9%
3.6%
Hepatitis C
1.0
0.4
U.S.
0.3
0.2
International
1.6
0.6
WW Ops excluding Hepatitis C only
10.0%
4.7%
U.S.
12.1%
6.9%
International
6.6%
2.3%
WW Ops excluding Acquisitions, Divestitures and Hepatitis C
(0.4)%
10.7%
3.1%
5.9%
U.S.
(1.5)%
13.0%
2.3%
7.3%
International
0.3%
7.0%
3.9%
4.2%
(1) Hepatitis C products include OLYSIO?/SOVRIAD?and INCIVO?
(2) Operational growth excludes the effect of translational currency
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions, Divestitures, and Hepatitis C Sales(1)
NINE MONTHS 2016 ACTUAL vs. 2015 ACTUAL
Segments
Consumer
Pharmaceutical
Medical Devices
Total
Operational %(2)
WW As Reported:
0.4%
9.1%
1.0%
4.5%
U.S.
1.1%
12.7%
1.5%
7.1%
International
0.1%
4.2%
0.5%
1.8%
Wound Care/Other
SPLENDA?
2.2
0.4
U.S.
4.3
0.7
International
0.9
0.2
Cardiovascular
Cordis
2.4
0.9
U.S.
1.1
0.4
International
3.5
1.3
Skin Care
(0.7)
Vogue
(1.9)
(0.1)
U.S.
0.0
(0.3)
International
0.0
All Other Acquisitions and Divestitures
(0.1)
0.4
0.0
0.1
U.S.
(0.3)
0.7
(0.1)
0.2
International
0.0
0.0
0.1
0.1
WW Ops excluding Acquisitions and Divestitures
1.8%
9.5%
3.4%
5.8%
U.S.
3.2%
13.4%
2.5%
8.1%
International
1.0%
4.2%
4.1%
3.4%
Hepatitis C
2.4
1.1
U.S.
1.1
0.6
International
4.2
1.6
WW Ops excluding Hepatitis C only
11.5%
5.6%
U.S.
13.8%
7.7%
International
8.4%
3.4%
WW Ops excluding Acquisitions, Divestitures, and Hepatitis C
1.8%
11.9%
3.4%
6.9%
U.S.
3.2%
14.5%
2.5%
8.7%
International
1.0%
8.4%
4.1%
5.0%
(1) Hepatitis C products include OLYSIO?/SOVRIAD?and INCIVO?
(2) Operational growth excludes the effect of translational currency
REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER
NINE MONTHS
% Change
% Change
2016
2015
Reported Operational (1) Currency
2016
2015
Reported Operational (1) Currency
CONSUMER SEGMENT (2)
BABY CARE
US
$
96
103
-6.8%
-6.8%
-
$
293
$
318 -7.9%
-7.9%
-
Intl
370
403
-8.2%
-5.3%
-2.9%
1,124
1,242
-9.5%
-2.5%
-7.0%
WW
466
506
-7.9%
-5.6%
-2.3%
1,417
1,560
-9.2%
-3.6%
-5.6%
ORAL CARE
US
156
154
1.3%
1.3%
-
485
459
5.7%
5.7%
-
Intl
227
224
1.3%
3.1%
-1.8%
686
713
-3.8%
1.8%
-5.6%
WW
383
378
1.3%
2.3%
-1.0%
1,171
1,172
-0.1%
3.3%
-3.4%
OTC
US
380
383
-0.8%
-0.8%
-
1,230
1,154
6.6%
6.6%
-
Intl
584
580
0.7%
3.5%
-2.8%
1,761
1,776
-0.8%
4.2%
-5.0%
WW
964
963
0.1%
1.8%
-1.7%
2,991
2,930
2.1%
5.1%
-3.0%
SKIN CARE
US
517
435
18.9%
18.9%
-
1,560
1,418
10.0%
10.0%
-
Intl
438
428
2.3%
5.3%
-3.0%
1,210
1,242
-2.6%
2.7%
-5.3%
WW
955
863
10.7%
12.2%
-1.5%
2,770
2,660
4.1%
6.6%
-2.5%
WOMEN’S HEALTH
US
3
6
-50.0%
-50.0%
-
16
19
-15.8%
-15.8%
-
Intl
266
304
-12.5%
-9.1%
-3.4%
787
898
-12.4%
-5.1%
-7.3%
WW
269
310
-13.2%
-9.9%
-3.3%
803
917
-12.4%
-5.3%
-7.1%
WOUND CARE / OTHER
US
139
196
-29.1%
-29.1%
-
449
623
-27.9%
-27.9%
-
Intl
85
98
-13.3%
-13.2%
-0.1%
274
325
-15.7%
-12.0%
-3.7%
WW
224
294
-23.8%
-23.8%
0.0%
723
948
-23.7%
-22.4%
-1.3%
TOTAL CONSUMER
US
1,291
1,277 1.1%
1.1%
-
4,033
3,991
1.1%
1.1%
-
Intl
1,970
2,037 -3.3%
-0.6%
-2.7%
5,842
6,196
-5.7%
0.1%
-5.8%
WW
$
3,261
3,314 -1.6%
0.1%
-1.7%
$
9,875
10,187
-3.1%
0.4%
-3.5%
REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER
NINE MONTHS
% Change
% Change
2016
2015
Reported Operational (1) Currency
2016
2015
Reported Operational (1) Currency
PHARMACEUTICAL SEGMENT (2)
IMMUNOLOGY
US
$
2,294
1,910 20.1%
20.1%
-
$
6,689
5,541
20.7%
20.7%
-
Intl
790
704
12.2%
11.6%
0.6%
2,343
2,090
12.1%
15.7%
-3.6%
WW
3,084
2,614 18.0%
17.8%
0.2%
9,032
7,631
18.4%
19.4%
-1.0%
REMICADE
US
1,222
1,117 9.4%
9.4%
-
3,669
3,260
12.5%
12.5%
-
US Exports (3)
255
180
41.7%
41.7%
-
673
602
11.8%
11.8%
-
Intl
306
316
-3.2%
-2.9%
-0.3%
1,000
1,019
-1.9%
3.4%
-5.3%
WW
1,783
1,613 10.5%
10.6%
-0.1%
5,342
4,881
9.4%
10.5%
-1.1%
SIMPONI / SIMPONI ARIA
US
256
199
28.6%
28.6%
-
716
526
36.1%
36.1%
-
Intl
225
181
24.3%
20.6%
3.7%
603
462
30.5%
31.3%
-0.8%
WW
481
380
26.6%
24.8%
1.8%
1,319
988
33.5%
33.9%
-0.4%
STELARA
US
561
414
35.5%
35.5%
-
1,631
1,153
41.5%
41.5%
-
Intl
253
199
27.1%
27.8%
-0.7%
722
579
24.7%
27.2%
-2.5%
WW
814
613
32.8%
33.0%
-0.2%
2,353
1,732
35.9%
36.7%
-0.8%
OTHER IMMUNOLOGY
US
-
-
-
-
-
-
-
-
-
-
Intl
6
8
-25.0%
-22.6%
-2.4%
18
30
-40.0%
-32.9%
-7.1%
WW
6
8
-25.0%
-22.6%
-2.4%
18
30
-40.0%
-32.9%
-7.1%
INFECTIOUS DISEASES
US
387
379
2.1%
2.1%
-
1,107
1,172
-5.5%
-5.5%
-
Intl
455
469
-3.0%
-2.2%
-0.8%
1,340
1,683
-20.4%
-18.5%
-1.9%
WW
842
848
-0.7%
-0.3%
-0.4%
2,447
2,855
-14.3%
-13.2%
-1.1%
EDURANT
US
13
11
18.2%
18.2%
-
38
29
31.0%
31.0%
-
Intl
136
100
36.0%
35.4%
0.6%
370
274
35.0%
35.2%
-0.2%
WW
149
111
34.2%
33.7%
0.5%
408
303
34.7%
34.9%
-0.2%
OLYSIO / SOVRIAD
US
13
26
-50.0%
-50.0%
-
50
174
-71.3%
-71.3%
-
Intl
8
53
-84.9%
-85.7%
0.8%
46
403
-88.6%
-88.2%
-0.4%
WW
21
79
-73.4%
-73.9%
0.5%
96
577
-83.4%
-83.1%
-0.3%
PREZISTA / PREZCOBIX / REZOLSTA
US
310
285
8.8%
8.8%
-
860
777
10.7%
10.7%
-
Intl
183
183
0.0%
2.0%
-2.0%
544
566
-3.9%
-1.1%
-2.8%
WW
493
468
5.3%
6.1%
-0.8%
1,404
1,343
4.5%
5.7%
-1.2%
OTHER INFECTIOUS DISEASES
US
51
57
-10.5%
-10.5%
-
159
192
-17.2%
-17.2%
-
Intl
128
133
-3.8%
-3.0%
-0.8%
380
440
-13.6%
-10.6%
-3.0%
WW
179
190
-5.8%
-5.2%
-0.6%
539
632
-14.7%
-12.6%
-2.1%
See footnotes at end of schedule
REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER
NINE MONTHS
% Change
% Change
2016
2015
Reported Operational (1) Currency
2016
2015
Reported Operational (1) Currency
NEUROSCIENCE
US
622
655
-5.0%
-5.0%
-
1,997
2,098
-4.8%
-4.8%
-
Intl
842
821
2.6%
0.0%
2.6%
2,618
2,560
2.3%
3.5%
-1.2%
WW
1,464
1,476 -0.8%
-2.2%
1.4%
4,615
4,658
-0.9%
-0.2%
-0.7%
CONCERTA / METHYLPHENIDATE
US
102
89
14.6%
14.6%
-
365
317
15.1%
15.1%
-
Intl
88
89
-1.1%
-2.5%
1.4%
294
291
1.0%
4.4%
-3.4%
WW
190
178
6.7%
6.0%
0.7%
659
608
8.4%
10.0%
-1.6%
INVEGA
US
28
82
-65.9%
-65.9%
-
70
281
-75.1%
-75.1%
-
Intl
59
57
3.5%
-1.0%
4.5%
185
179
3.4%
2.7%
0.7%
WW
87
139
-37.4%
-39.2%
1.8%
255
460
-44.6%
-44.9%
0.3%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA
US
339
277
22.4%
22.4%
-
983
758
29.7%
29.7%
-
Intl
217
182
19.2%
18.8%
0.4%
646
548
17.9%
19.8%
-1.9%
WW
556
459
21.1%
20.9%
0.2%
1,629
1,306
24.7%
25.5%
-0.8%
RISPERDAL CONSTA
US
94
103
-8.7%
-8.7%
-
289
306
-5.6%
-5.6%
-
Intl
128
132
-3.0%
-3.9%
0.9%
394
430
-8.4%
-7.1%
-1.3%
WW
222
235
-5.5%
-6.0%
0.5%
683
736
-7.2%
-6.4%
-0.8%
OTHER NEUROSCIENCE
US
59
104
-43.3%
-43.3%
-
290
436
-33.5%
-33.5%
-
Intl
350
361
-3.0%
-7.3%
4.3%
1,099
1,112
-1.2%
-0.6%
-0.6%
WW
409
465
-12.0%
-15.3%
3.3%
1,389
1,548
-10.3%
-9.9%
-0.4%
ONCOLOGY
US
622
394
57.9%
57.9%
-
1,740
1,090
59.6%
59.6%
-
Intl
895
776
15.3%
15.4%
-0.1%
2,605
2,332
11.7%
14.1%
-2.4%
WW
1,517
1,170 29.7%
29.7%
0.0%
4,345
3,422
27.0%
28.7%
-1.7%
IMBRUVICA
US
179
98
82.7%
82.7%
-
455
253
79.8%
79.8%
-
Intl
170
86
97.7%
*
**
450
201
*
*
**
WW
349
184
89.7%
92.1%
-2.4%
905
454
99.3%
*
**
VELCADE
US
-
-
-
-
-
-
-
-
-
-
Intl
304
329
-7.6%
-7.4%
-0.2%
950
1,012
-6.1%
-3.7%
-2.4%
WW
304
329
-7.6%
-7.4%
-0.2%
950
1,012
-6.1%
-3.7%
-2.4%
ZYTIGA
US
282
276
2.2%
2.2%
-
840
784
7.1%
7.1%
-
Intl
300
272
10.3%
8.5%
1.8%
901
866
4.0%
5.4%
-1.4%
WW
582
548
6.2%
5.3%
0.9%
1,741
1,650
5.5%
6.3%
-0.8%
OTHER ONCOLOGY
US
161
20
*
*
-
445
53
*
*
-
Intl
121
89
36.0%
36.6%
-0.6%
304
253
20.2%
23.0%
-2.8%
WW
282
109
*
*
**
749
306
*
*
**
CARDIOVASCULAR / METABOLISM / OTHER
US
1,117
1,171 -4.6%
-4.6%
-
3,590
3,522
1.9%
1.9%
-
Intl
376
415
-9.4%
-7.4%
-2.0%
1,203
1,278
-5.9%
-1.5%
-4.4%
WW
1,493
1,586 -5.9%
-5.4%
-0.5%
4,793
4,800
-0.1%
1.1%
-1.2%
XARELTO
US
529
461
14.8%
14.8%
-
1,690
1,374
23.0%
23.0%
-
Intl
-
-
-
-
-
-
-
-
-
-
WW
529
461
14.8%
14.8%
-
1,690
1,374
23.0%
23.0%
-
INVOKANA / INVOKAMET
US
294
322
-8.7%
-8.7%
-
939
890
5.5%
5.5%
-
Intl
34
18
88.9%
94.3%
-5.4%
97
46
*
*
**
WW
328
340
-3.5%
-3.2%
-0.3%
1,036
936
10.7%
11.3%
-0.6%
PROCRIT / EPREX
US
168
177
-5.1%
-5.1%
-
581
519
11.9%
11.9%
-
Intl
82
86
-4.7%
-4.7%
0.0%
265
289
-8.3%
-5.5%
-2.8%
WW
250
263
-4.9%
-4.9%
0.0%
846
808
4.7%
5.7%
-1.0%
OTHER
US
126
211
-40.3%
-40.3%
-
380
739
-48.6%
-48.6%
-
Intl
260
311
-16.4%
-14.1%
-2.3%
841
943
-10.8%
-6.3%
-4.5%
WW
386
522
-26.1%
-24.7%
-1.4%
1,221
1,682
-27.4%
-24.9%
-2.5%
TOTAL PHARMACEUTICAL
US
5,042
4,509
11.8%
11.8%
-
15,123
13,423
12.7%
12.7%
-
Intl
3,358
3,185
5.4%
5.0%
0.4%
10,109
9,943
1.7%
4.2%
-2.5%
WW
$
8,400
7,694
9.2%
9.0%
0.2%
$
25,232
23,366
8.0%
9.1%
-1.1%
See footnotes at end of schedule
REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER
NINE MONTHS
% Change
% Change
2016
2015
Reported
Operational (1) Currency
2016
2015
Reported Operational (1) Currency
MEDICAL DEVICES SEGMENT (2) (4)
CARDIOVASCULAR
US
$
235
239
-1.7%
-1.7%
-
$
701
702
-0.1%
-0.1%
-
Intl
216
285
-24.2%
-26.8%
2.6%
663
895
-25.9%
-25.6%
-0.3%
WW
451
524
-13.9%
-15.3%
1.4%
1,364
1,597
-14.6%
-14.4%
-0.2%
DIABETES CARE
US
191
205
-6.8%
-6.8%
-
548
631
-13.2%
-13.2%
-
Intl
236
265
-10.9%
-11.2%
0.3%
779
817
-4.7%
-2.2%
-2.5%
WW
427
470
-9.1%
-9.2%
0.1%
1,327
1,448
-8.4%
-7.0%
-1.4%
DIAGNOSTICS
US
-
-
-
-
-
-
-
-
-
-
Intl
7
16
-56.3%
-55.8%
-0.5%
66
62
6.5%
21.1%
-14.6%
WW
7
16
-56.3%
-55.8%
-0.5%
66
62
6.5%
21.1%
-14.6%
ORTHOPAEDICS
US
1,343
1,312
2.4%
2.4%
-
4,099
3,942
4.0%
4.0%
-
Intl
908
869
4.5%
4.5%
0.0%
2,848
2,897
-1.7%
0.9%
-2.6%
WW
2,251
2,181
3.2%
3.2%
0.0%
6,947
6,839
1.6%
2.7%
-1.1%
HIPS
US
190
185
2.7%
2.7%
-
590
568
3.9%
3.9%
-
Intl
130
124
4.8%
6.4%
-1.6%
421
410
2.7%
6.5%
-3.8%
WW
320
309
3.6%
4.2%
-0.6%
1,011
978
3.4%
5.0%
-1.6%
KNEES
US
223
214
4.2%
4.2%
-
696
662
5.1%
5.1%
-
Intl
132
129
2.3%
4.0%
-1.7%
433
429
0.9%
4.3%
-3.4%
WW
355
343
3.5%
4.1%
-0.6%
1,129
1,091
3.5%
4.8%
-1.3%
TRAUMA
US
389
368
5.7%
5.7%
-
1,151
1,083
6.3%
6.3%
-
Intl
248
239
3.8%
3.1%
0.7%
764
801
-4.6%
-2.1%
-2.5%
WW
637
607
4.9%
4.6%
0.3%
1,915
1,884
1.6%
2.7%
-1.1%
SPINE & OTHER
US
541
545
-0.7%
-0.7%
-
1,662
1,629
2.0%
2.0%
-
Intl
398
377
5.6%
5.0%
0.6%
1,230
1,257
-2.1%
0.0%
-2.1%
WW
939
922
1.8%
1.6%
0.2%
2,892
2,886
0.2%
1.1%
-0.9%
SURGERY
US
1,002
987
1.5%
1.5%
-
3,003
2,947
1.9%
1.9%
-
Intl
1,282
1,233
4.0%
3.9%
0.1%
3,906
3,857
1.3%
4.3%
-3.0%
WW
2,284
2,220
2.9%
2.9%
0.0%
6,909
6,804
1.5%
3.2%
-1.7%
ADVANCED
US
390
357
9.2%
9.2%
-
1,131
1,046
8.1%
8.1%
-
Intl
494
438
12.8%
13.0%
-0.2%
1,478
1,359
8.8%
11.9%
-3.1%
WW
884
795
11.2%
11.3%
-0.1%
2,609
2,405
8.5%
10.3%
-1.8%
GENERAL
US
414
427
-3.0%
-3.0%
-
1,254
1,272
-1.4%
-1.4%
-
Intl
649
656
-1.1%
-1.1%
0.0%
2,006
2,063
-2.8%
0.0%
-2.8%
WW
1,063
1,083
-1.8%
-1.8%
0.0%
3,260
3,335
-2.2%
-0.5%
-1.7%
SPECIALTY
US
198
203
-2.5%
-2.5%
-
618
629
-1.7%
-1.7%
-
Intl
139
139
0.0%
-1.2%
1.2%
422
435
-3.0%
0.3%
-3.3%
WW
337
342
-1.5%
-2.0%
0.5%
1,040
1,064
-2.3%
-1.0%
-1.3%
VISION CARE
US
277
262
5.7%
5.7%
-
767
758
1.2%
1.2%
-
Intl
462
421
9.7%
5.3%
4.4%
1,297
1,202
7.9%
7.7%
0.2%
WW
739
683
8.2%
5.5%
2.7%
2,064
1,960
5.3%
5.2%
0.1%
TOTAL MEDICAL DEVICES
US
3,048
3,005
1.4%
1.4%
-
9,118
8,980
1.5%
1.5%
-
Intl
3,111
3,089
0.7%
-0.2%
0.9%
9,559
9,730
-1.8%
0.5%
-2.3%
WW
$
6,159
6,094
1.1%
0.7%
0.4%
$
18,677
18,710
-0.2%
1.0%
-1.2%
* Percentage greater than 100%
** Not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Reported as U.S. sales
(4) Prior year amounts have been reclassified to conform to current year product disclosure

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2016-third-quarter-results-300346521.html

SOURCE Johnson & Johnson

http://rt.prnewswire.com/rt.gif?NewsItemId=NY19407&Transmission_Id=201610180640PR_NEWS_USPR_____NY19407&DateId=20161018